Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism

Biogen has achieved significant regulatory and clinical milestones for its Alzheimer’s treatment Leqembi, positioning the biotechnology firm for potential growth in international markets. The company’s recent successes span multiple continents and are supported by compelling long-term efficacy data.

The pharmaceutical company secured approval for Leqembi’s maintenance dose in China on September 28th, followed shortly by regulatory clearance in Australia. These developments open access to substantial new markets for the Alzheimer’s therapy.

Supporting these regulatory achievements, four-year data from the Clarity-AD study demonstrates impressive clinical benefits. The treatment showed a significant slowing of cognitive decline, measured at 1.75 points on the CDR-SB scale, providing robust evidence of Leqembi’s sustained effectiveness.

Concurrent with these developments,... Read more...